# REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

> **NCT01252953** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 30449 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Anacetrapib
- **DRUG:** Placebo anacetrapib

## Key facts

- **NCT ID:** NCT01252953
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-06
- **Primary completion:** 2017-01-31
- **Final completion:** 2037-01-31
- **Target enrollment:** 30449 (ACTUAL)
- **Last updated:** 2024-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01252953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01252953, "REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01252953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*